2022
Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer
Marczyk M, Qing T, O’Meara T, Yagahoobi V, Pelekanou V, Bai Y, Reisenbichler E, Cole KS, Li X, Gunasekharan V, Ibrahim E, Fanucci K, Wei W, Rimm DL, Pusztai L, Blenman KRM. Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. Npj Breast Cancer 2022, 8: 88. PMID: 35869114, PMCID: PMC9307813, DOI: 10.1038/s41523-022-00449-3.Peer-Reviewed Original ResearchTumor immune microenvironmentImmune microenvironmentTriple-negative breast cancer tissuesTriple-negative breast cancerAfrican AmericansImmune checkpoint inhibitorsTumor mutation burdenNegative breast cancerBreast cancer tissuesImmune-related pathwaysStromal TILsCheckpoint inhibitorsImmune exclusionClinical outcomesPD-L1Self-identified African AmericansCancer patientsImmune infiltrationBreast cancerMutation burdenCancer tissuesPredictive signatureMRNA expressionTherapeutic agentsPatientsExamination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, Podoll M, Rabe K, Sanders MA, Singh K, Snir OL, Soong TR, Wei S, Wen H, Wong S, Yoon E, Pusztai L, Reisenbichler E, Rimm DL. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncology 2022, 8: 1-4. PMID: 35113160, PMCID: PMC8814969, DOI: 10.1001/jamaoncol.2021.7239.Peer-Reviewed Original ResearchConceptsBreast cancer biopsiesT-DXdCancer biopsiesLarge randomized clinical trialsRandomized clinical trialsERBB2 protein expressionCentral pathology laboratoryBreast cancer tissuesAmerican Pathologists surveysStudy of concordanceTrastuzumab deruxtecanERBB2 positivityPatient populationClinical trialsScore 0Breast cancerImmunohistochemistry scoreCancer tissuesIHC assaysPatientsPathology laboratoryProtein expressionBiopsyIHCConcordance
2020
Gene Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer
Liedtke C, Pusztai L. Gene Expression Profiling as an Emerging Diagnostic Tool to Personalize Chemotherapy Selection for Early Stage Breast Cancer. 2020, 77-96. DOI: 10.1201/9780429137723-6.Peer-Reviewed Original ResearchBreast cancerEarly-stage breast cancerCombination chemotherapy regimensSubstantial tumor responseAdvanced breast cancerNeoadjuvant chemotherapy regimenStage breast cancerAdjuvant chemotherapyChemotherapy regimenNeoadjuvant therapyChemotherapy regimensPreoperative chemotherapyChemotherapy selectionOverall survivalInoperable cancerTumor responseStage ICancer tissuesCancerGene expression profilingChemotherapyDiagnostic toolCurrent standardSemiquantitative mannerExpression profiling
2019
Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
Wali VB, Patwardhan GA, Pelekanou V, Karn T, Cao J, Ocana A, Yan Q, Nelson B, Hatzis C, Pusztai L. Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer. Scientific Reports 2019, 9: 14934. PMID: 31624295, PMCID: PMC6797726, DOI: 10.1038/s41598-019-51453-w.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBreastCell Line, TumorCell MembraneCell ProliferationDatasets as TopicDrug DevelopmentFemaleGABA-A Receptor AntagonistsGene Expression ProfilingGene Knockdown TechniquesHumansImmunoconjugatesImmunoglobulin Fab FragmentsMaytansineMiceMolecular Targeted TherapyReceptors, GABA-ATriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysConceptsTriple-negative breast cancerNegative breast cancerTNBC cell growthBreast cancerMDA-MB-468 xenograftsPotential novel therapeutic targetNovel biologic targetsNovel therapeutic targetBreast cancer tissuesReceptors/cellAntibody-drug conjugate (ADC) developmentMost normal tissuesTreatment optionsCell growthTherapeutic targetBiologic targetsNude miceCancer tissuesVivo functional assaysLow expressionNormal tissuesNovel targetCancerSignificant anticancer activityADC development
2018
Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide.
Li X, Warren S, Pelekanou V, Wali V, Cesano A, Liu M, Danaher P, Elliott N, Nahleh Z, Hayes D, Hortobagyi G, Barlow W, Hatzis C, Pusztai L. Immune profiling of pre- and post-treatment breast cancer tissues from the S0800 randomized neoadjuvant trial of weekly nab-paclitaxel with or without bevacizumab and dose dense doxorubicin and cyclophosphamide. Journal Of Clinical Oncology 2018, 36: 578-578. DOI: 10.1200/jco.2018.36.15_suppl.578.Peer-Reviewed Original Research
2017
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Pelekanou V, Carvajal-Hausdorf DE, Altan M, Wasserman B, Carvajal-Hausdorf C, Wimberly H, Brown J, Lannin D, Pusztai L, Rimm DL. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Research 2017, 19: 91. PMID: 28784153, PMCID: PMC5547502, DOI: 10.1186/s13058-017-0884-8.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesPD-L1 expressionTumor-infiltrating lymphocytesRecurrence-free survivalNeoadjuvant chemotherapyResidual cancer tissueTIL countBreast cancerCancer tissuesDeath ligand 1 (PD-L1) protein expressionNode-positive breast cancerImproved recurrence-free survivalPD-L1 protein expressionHigher TIL countsPD-L1 statusProtein expressionBreast cancer patientsBreast cancer tissuesPost-treatment samplesPrechemotherapy samplesTIL infiltrationResidual cancerImmune markersResidual diseasePatient cohort
2007
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer
Andre F, Nahta R, Conforti R, Boulet T, Aziz M, Yuan LX, Meslin F, Spielmann M, Tomasic G, Pusztai L, Hortobagyi GN, Michiels S, Delaloge S, Esteva FJ. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Annals Of Oncology 2007, 19: 315-320. PMID: 17804473, DOI: 10.1093/annonc/mdm429.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBiomarkers, TumorBreast NeoplasmsChi-Square DistributionCohort StudiesCombined Modality TherapyDisease-Free SurvivalErbB ReceptorsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryMiddle AgedNeoplasm StagingPredictive Value of TestsProbabilityProportional Hazards ModelsProto-Oncogene Proteins c-aktRandomized Controlled Trials as TopicReceptor, ErbB-2Risk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsEarly breast cancerBreast cancerPredictive valuePhosphorylated AktAdjuvant chemotherapyPAkt expressionAnthracycline-based adjuvant chemotherapyEarly-stage breast cancerEpidermal growth factor receptor expressionGrowth factor receptor expressionAkt phosphorylationBreast cancer tissuesFactor receptor expressionGrowth factor receptorHER2 tumorsRandomized trialsAssessable tumorsHER2 expressionReceptor expressionPositive stainingCancer tissuesEGFR expressionHER2Tumor resistancePatients
2005
Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo
Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo. Cell Cycle 2005, 4: 1149-1152. PMID: 16103753, DOI: 10.4161/cc.4.9.2038.Peer-Reviewed Original ResearchMeSH KeywordsAlternative SplicingBreast NeoplasmsCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Expression RegulationHumansImmunohistochemistryIn Vitro TechniquesInhibitory Concentration 50Microtubule-Associated ProteinsMicrotubulesModels, BiologicalOligonucleotide Array Sequence AnalysisPaclitaxelRNA, MessengerRNA, Small InterferingTau ProteinsTubulinConceptsPaclitaxel sensitivityHuman breast cancer tissuesBreast cancer tissuesHuman breast cancerRole of tauCell linesRegulation of tauBreast cancerCancer tissuesProtein tauNovel markerLow expressionMicrotubule associated proteinNovel mediatorPaclitaxelTauPhysiological levelsGene expression analysisRecent findingsMediatorsMarkersAssociated proteinsChemotherapyCancerExpression analysis
2001
Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry
Esteva F, Hortobagyi G, Sahin A, Smith T, Chin D, Liang S, Pusztai L, Buzdar A, Bacus S. Expression of erbB/HER receptors, heregulin and p38 in primary breast cancer using quantitative immunohistochemistry. Pathology & Oncology Research 2001, 7: 171-177. PMID: 11692142, DOI: 10.1007/bf03032345.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerHER-2Mitogen-activated protein kinaseQuantitative immunohistochemistryHER-4Frequency of expressionGrowth factor receptorHER-3Early-stage breast cancerFactor receptorHormone receptor statusInvasive breast cancerErbB/Breast cancer tissuesExpression of EGFRYears of ageEvidence of associationReceptor statusLymph nodesTumor sizeHER familyTumor markersTumor specimensCancer tissues